Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9NL3R
|
|||
| Drug Name |
Trebananib
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [1] | |
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 2 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [3] | ||
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiopoietin-1 (ANGPT1) | Target Info | Inhibitor | [4] |
| Angiopoietin-2 (ANGPT2) | Target Info | Inhibitor | [4] | |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| FSH Signaling Pathway | ||||
| Panther Pathway | Angiogenesis | |||
| Pathway Interaction Database | Angiopoietin receptor Tie2-mediated signaling | |||
| SHP2 signaling | ||||
| Reactome | Tie2 Signaling | |||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Cell surface interactions at the vascular wall | |||
| Angiogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01281254) AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00467025) AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT02525536) A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 4 | Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.